Pathstone Holdings
XERS icon

Pathstone Holdings’s Xeris Biopharma Holdings XERS Stock Holding History

Pathstone Holdings’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,098
Closed -$40K – 2391
2024
Q1 		$40K Buy
+18,098
New +$46.8K ﹤0.01% 2264

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Pathstone Holdings's XERS Position: Q2 2024 in Review

Pathstone Holdings sold out of Xeris Biopharma Holdings (XERS) in Q2 2024, closing a stake of 18,098 shares — an estimated $40K sold.

Pathstone Holdings first reported a position in XERS in Q1 2024 and held it in 1 quarter. The position peaked at $40K in Q1 2024. 134 funds tracked by Wall St. Rank hold XERS as of Q2 2024.

  • Pathstone Holdings reported no remaining Xeris Biopharma Holdings position as of Q2 2024 after selling out during the quarter.
  • Pathstone Holdings sold 18,098 Xeris Biopharma Holdings shares in Q2 2024, an estimated $40K.
  • Pathstone Holdings first reported a position in Xeris Biopharma Holdings in Q1 2024 and held it in 1 quarter.
  • Pathstone Holdings's Xeris Biopharma Holdings position peaked at $40K in Q1 2024.
  • 134 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2024.

Based on Pathstone Holdings's 13F filing for Q2 2024, filed 14 Aug 2024.